Paul D Gamlin

Title: Paul D. Gamlin: Innovator in Gene Delivery Technologies

Introduction

Paul D. Gamlin is a notable inventor based in Birmingham, AL (US), recognized for his contributions to gene delivery technologies. With a total of 3 patents, he has made significant strides in the field of adeno-associated viral (AAV) particles, particularly in their application for retinal gene therapy.

Latest Patents

Among his latest patents, Gamlin has developed modified AAV capsid proteins and their uses. These AAV particles are emerging as effective vehicles for gene delivery to various organs and tissues, including the retina. His work includes the provision of variant AAV capsid proteins, such as variant serotype 2 (AAV2), which exhibit enhanced abilities to transduce retinal cells.

Career Highlights

Gamlin has worked with esteemed organizations, including the University of Florida Research Foundation and the UAB Research Foundation. His innovative research has positioned him as a key figure in the advancement of gene therapy technologies.

Collaborations

Throughout his career, Gamlin has collaborated with notable colleagues, including Sergei Zolotukhin and Sanford Leon Boye. These partnerships have further enriched his research and contributions to the field.

Conclusion

Paul D. Gamlin's work in the development of modified AAV capsid proteins highlights his significant impact on gene delivery technologies. His innovative patents and collaborations continue to pave the way for advancements in retinal gene therapy.